Category: News
-
Global Fund replenishment: the Gulf Cooperation Council (GCC) must announce its pledge before the next Board Meeting
Statement from 46 Organizations Wednesday, December 3rd, 2025 As the world faces unprecedented health challenges, the Middle East and North Africa (MENA) region is entering a critical phase marked by an accelerating health crisis. The region is experiencing the fastest-growing HIV epidemic globally, alongside a rising burden of tuberculosis and fragile health systems in several…
-
A Powerful Tribute to Professor Hakima Himmich: A Life of Courage, Justice, and Resistance
🗓️ On May 13, 2025, during the 3rd Global Summit on Intellectual Property and Access to Medicines (GSIPA2M2025) held in Marrakech and co-organized by ITPC-MENA, a deeply emotional moment captured the audience. A powerful tribute was paid to Professor Hakima Himmich, a true icon in the fight for health and social justice – in Morocco, across the MENA region, and far…
-
HIV PREVENTION & ACCOUNTABILITY: A MULTI-COUNTRY COMMUNITY PERSPECTIVE 2025
This report provides a civil society analysis of the HIV prevention response, outlining the progress and gaps in five countries: Egypt, Jordan, Lebanon, Morocco, and Tunisia. The findings inform a set of key recommendations aimed at addressing these urgent challenges and strengthening the response in MENA. DOWNLOAD PDF تنزيل ملف PDF TÉLÉCHARGER PDF Frontline AIDS…
-
The MENA H Coalition calls for sustained investments in the fight against tuberculosis in the MENA region
Joint press release FOR IMMEDIATE RELEASE MENA-H coalition urges urgent action to combat tuberculosis in the region, with emphasis on innovation and universal health coverage 2025, March 24 – On World Tuberculosis Day, the MENA-H Coalition issues an urgent call to intensify efforts to eliminate tuberculosis (TB) in the Middle East and North Africa (MENA)…
-
Results of a study on lenacapavir and two broadly neutralizing antibodies were presented at CROI 2025.
At the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, results were presented from a Phase II study examining the efficacy of a combination of lenacapavir (TN Sunlenca) and two broadly neutralizing antibodies (bNAbs) – teropavimab and zinlirvimab. The study results indicate that this regimen could form the basis of a complete…
-
In Argentina, Gilead’s patent applications for lenacapavir have been rejected
The National Institute of Industrial Property of Argentina (INPI) has rejected patent applications from Gilead for the drug lenacapavir – an innovative long-acting injectable drug that has proven effective as an option for PrEP and the treatment of HIV with multi-drug resistance. Previously, the Argentine organization FGEP (Foundation for the Study and Research of Patent…
-
ViiV HEALTHCARE TO TRIPLE ANNUAL SUPPLY OF LONG-ACTING HIV PREP FOR LOW- AND MIDDLE-INCOME COUNTRIES: A REAL RACE IS STARTING AMONG PHARMACEUTICAL COMPANIES FOR MARKET SHARE AND PROFIT
Source : ITPC EECA Against the backdrop of a recent press release from Gilead announcing the signing of a voluntary license for the new drug lenacapavir, ViiV Healthcare has announced an increase in the supply of its injectable drug cabotegravir. This sequence of events inevitably raises the thought that a real race is starting among…
-
HIV Community-Based Organizations are Fighting Patent Monopolies on Lenacapavir
Source : ITPC Global Despite the world’s efforts, there have been over a million new cases of HIV each year. Lenacapavir (LEN), a long-acting antiretroviral, could change the trajectory of the global HIV epidemic, but Gilead’s patent monopoly will keep LEN unaffordable in many countries with urgent need for it. The PURPOSE-1 HIV prevention trial…
-
MENACAB 2021 – 2022 REPORT : TREATMENT ACCESS IN TIME OF PANDEMICS
Since the beginning of the HIV epidemic, Community Advisory Boards (CABs) constituted an effective tool to link communities as real partners with researchers and drug manufacturers; educate people living with HIV and their advocates, disseminate information about research and drug development, and to discuss access strategies. The first meeting of MENACAB took place in 2014.…
-
Othmane MARRAKCHI: ITPC-MENA’s new Advocacy Officer.
ITPC-MENA is pleased to inform you that Mr. Othmane MARRAKCHI has recently joined ITPC-MENA as Advocacy Officer for Access to Medicines. In this position, Mr. Othmane MARRAKCHI will manage the development and implementation of the ITPC-MENA project on the use of TRIPS1 flexibilities to enable access to HIV, HCV, and tuberculosis treatments in developing countries.…